Stable neurological function in subjects treated with 23-dideoxyinosine

References

• Balis F M, Pizzo P A, Murphy R F, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279–285
   PubMed Web of Science ®Google Scholar
• Butler K M, Husson R N, Balis F M, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 324: 137–144
   PubMed Web of Science ®Google Scholar
• Choo V. Combination superior to zidovudine in Delta trial. Lancet 1995; 342: 895
   Google Scholar
• Connolly K J, Allan J D, Fitch H, et al. Phase I study of 2′‐3′ dideoxyinosine administered orally twice daily to patients with AIDS or AIDS‐related complex and hematologic intolerance to zidovudine. Am J Med 1991; 91: 471–478
   PubMed Web of Science ®Google Scholar
• Darbyshire J H, Aboulker J P. Didanosine for zidovudine‐intolerant patients with HIV disease. Lancet 1992; 340: 1346–1347
   PubMedGoogle Scholar
• Dolin R, Amato D A, Fischl M A, et al. Zidovudine compared with didanosine in patients with advanced HrV Type I infection and little or no previous experience with zidovudine. Arch Intern Med 1995; 155: 961–974
   PubMed Web of Science ®Google Scholar
• Gray F, Belec L, Keohane C, et al. Zidovudine therapy and HIV encephalitis: a 10‐year neuropathological survey. AIDS 1994; 8: 489–493
   PubMedGoogle Scholar
• Hamilton J D, Hartigan P M, Simberkoff M S, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437–443
   PubMed Web of Science ®Google Scholar
• Hartman N R, Yarchoan R, Pluda J M, et al. Pharmacokinetics of 2′,3′‐dideoxy‐inosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990; 47: 647–654
   PubMed Web of Science ®Google Scholar
• Kahn J O, Lagakos S W, Richman D D, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 217: 581–587
   Google Scholar
• Kieburtz B C D, Seidlin M, Lambert J S, Dolin R, Reichman R, Valentine F. Extended follow‐up of peripheral neuropathy in patients with AIDS and AIDS‐related complex treated with dideoxyinosine. J AIDS 1992; 5: 60–64
   PubMedGoogle Scholar
• Klecker R W, Jr, Collins J M, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′ azido‐3′ deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407–412
   PubMed Web of Science ®Google Scholar
• McArthur J C, Hoover D R, Bacellar H, et al. Dementia in AIDS patients: Incidence and risk factors. Neurology 1993; 43: 2245–2252
   PubMed Web of Science ®Google Scholar
• Moyle G J, Nelson M R, Hawkins D, Gazzard B G. The use and toxicity of didanosine (DDI) in HIV antibody‐positive individuals intolerant to zidovudine (AZT). Quarterly J Med 1993; 86: 155–163
   PubMedGoogle Scholar
• Nordic Medica Research Councils HTV Therapy Group. Double blind dose‐response study of zidovudine in AIDS and advanced HIV infection. Br Med J 1992; 304: 13–17
   Google Scholar
• Pizzo P A, Eddy J, Fallon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319: 889–896
   PubMed Web of Science ®Google Scholar
• Portegies P, De Gans J, Lange J M A, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br Med J 1989; 299: 819–821
   PubMed Web of Science ®Google Scholar
• Portegies P, Enting R H, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow‐up in Amsterdam. The Netherlands. AIDS 1993; 7: 669–675
   PubMed Web of Science ®Google Scholar
• Portegies P, Entind R H, de Jong M D, et al. AIDS dementia complex and didanosine. Lancet 1994; 344: 759
   PubMedGoogle Scholar
• Price R W, Brew B J, Sidtis J, Rosenblum M, Check A C, Cleary P. The brain in AIDS: Central nervous system HIV‐1 infection in AIDS dementia complex. Science 1988; 239: 586–592
   PubMed Web of Science ®Google Scholar
• Price R A, Sidtis J J. Evaluation of the AIDS dementia complex in clinical trials. J AIDS 1990; 3(Suppl. 2)S51–S60
   Google Scholar
• Rathbun R C, Martin E S. Didanosine therapy in patients intolerant of or failing zidovudine therapy. Ann Pharmacol 1992; 26: 1347–1351
   Google Scholar
• Schmitt F A, Bigley J W, McKinnis R, et al. Neuropsychological outcome of azidothymidine (AZT) in the treatment of AIDS and AIDS‐related complex: A double blind, placebo‐controlled trial. N Engl J Med 1988; 319: 1573–1578
   PubMed Web of Science ®Google Scholar
• Sidtis J J. Evaluation of the AIDS dementia complex in adults. Association for Besearch in Nervous and Mental Disease 1994; 72: 273–287
   Google Scholar
• Sidtis J J, Gatsonis C, Price R W, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo‐controlled trial. Ann Neurol 1993; 33: 343–349
   PubMed Web of Science ®Google Scholar
• Spencer D C, Price R W. Human immunodeficiency virus and the central nervous system. Ann Rev Microbiol 1992; 46: 655–693
   PubMed Web of Science ®Google Scholar
• Spruance S L, Pavia A T, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV‐infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double‐blind clinical trial. Ann Int Med 1994; 120: 360–368
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Berg G, Brouwers P, et al. Response of human immunodeficiency virus associated neurological disease to 3′‐azido‐3′deoxythymidine. Lancet 1987; 1: 132–135
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Broder S. Anti‐retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. Pharmacol Ther 1989; 40: 329–348
   PubMedGoogle Scholar
• Wei L J, Johnson W E. Combining dependent tests with incomplete repeated measurements. Biometrika 1985; 72: 359–364
   Web of Science ®Google Scholar